# Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

> **NCT01237288** · PHASE3 · COMPLETED · sponsor: **Zeria Pharmaceutical** · enrollment: 16 (actual)

## Conditions studied

- Primary Hypophosphatemic Rickets

## Interventions

- **DRUG:** Z-521

## Key facts

- **NCT ID:** NCT01237288
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-04
- **Final completion:** 2013-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237288, "Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01237288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*